Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

E 6201

Next Previous
Drug Profile

E 6201

Alternative Names: E-6201; MEK-1/MEKK-1 Inhibitor - Eisai

Latest Information Update: 28 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eisai Medical Research
  • Developer Eisai Co Ltd; Mayo Clinic; National Cancer Institute (USA); Strategia Therapeutics; University of Arizona; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Lactones; Resorcinols
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; MAP kinase kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • No development reported Brain metastases; Solid tumours
  • Discontinued Plaque psoriasis

Most Recent Events

  • 28 Oct 2025 No recent reports of development identified for phase-I development in Brain metastases(Combination therapy, Second-line therapy or greater) in USA (IV, Injection)
  • 02 Jun 2025 Mayo Clinic terminates a phase-I trial for Brain metastases (Second-line therapy or greater, Combination therapy) in USA due to financial issues (NCT05388877)
  • 05 Apr 2024 Efficacy and adverse events data from a phase I trial in Brain metastases presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top